Kidney disease and COVID-19 disease severity—systematic review and meta-analysis
Authors:
- Jagmeet SinghJSJagmeet Singh
- Preeti MalikPMPreeti Malik
- Nidhi PatelNPNidhi Patel
- Suveenkrishna PothuruSPSuveenkrishna Pothuru
- Avantika IsraniAIAvantika Israni
- Raja Chandra ChakinalaRCRaja Chandra Chakinala
- Maryam Rafaqat HussainMHMaryam Rafaqat Hussain
- Anusha ChidharlaACAnusha Chidharla
- Harshil PatelHPHarshil Patel
- Saurabh Kumar PatelSPSaurabh Kumar Patel
- Rizwan RabbaniRRRizwan Rabbani
- Urvish PatelUrvish Patel
- 23 April 2021
- journal article
- review article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 22 (1) , 125-135
Abstract
We aimed to identify prevalence and association of comorbid chronic kidney disease (CKD), acute kidney injury (AKI) and utilization prevalence of continuous renal replacement therapy (CRRT) in COVID-19-hospitalized patients as a function of severity status. With the ongoing struggle across the globe to combat COVID-19 disease, published literature has described the role of kidney disease in COVID-19 patients based on single/multicenter experiences across the globe. We extracted data from observational studies describing comorbid CKD, AKI and CRRT and outcomes and severity of COVID-19-hospitalized patients from December 1, 2019–August 20, 2020 following PRISMA guidelines. Severity of COVID-19 includes intensive care unit admission, oxygen saturation < 90%, invasive mechanical ventilation utilization, in-hospital admission and mortality. Meta-analysis was performed using a random-effects model to calculate pooled estimates, and forest plots were created. In total, 29 studies with 15,017 confirmed COVID-19 patients were included. The overall prevalence of AKI was 11.6% [(430/3693)], comorbid CKD 9.7% [(1342/13,728)] and CRRT 2.58% [(102/3946)] in our meta-analysis. We also found higher odds of comorbid CKD (pooled OR: 1.70; 95%CI: 1.21–2.40; p = 0.002), AKI (8.28; 4.42–15.52; p < 0.00001) and utilization of CRRT (16.90; 9.00–31.74; p < 0.00001) in patients with severe COVID-19 disease. Conclusion Our meta-analysis suggests that comorbid CKD, AKI and utilization of CRRT were significantly associated with COVID-19 disease severity. Clinicians should focus on early triaging of COVID-19 patients with comorbid CKD and at risk for AKI to prevent complication and mortality.Keywords
This publication has 51 references indexed in Scilit:
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, ChinaClinical Infectious Diseases, 2020
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, ChinaIntensive Care Medicine, 2020
- Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, ChinaAllergy, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfallsCritical Care, 2018
- Early Initiation of Continuous Renal Replacement Therapy Improves Clinical Outcomes in Patients With Acute Respiratory Distress SyndromeThe American Journal of the Medical Sciences, 2015
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000